Who are Brimonidine Tartrate Gel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dexmetomidine intravenously, Dexmedetomidine 0.5μg／kg, Brinzolamide/Brimonidine FC, ropivacaine mixed with dexmedetomidine, Low-dose Dexmedetomidine, Combigan Two Times Daily (BID).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/brimonidine-tartrate-gel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Brimonidine Tartrate Gel — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Brimonidine Tartrate Gel (Brimonidine Tartrate Gel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic agonist. Area: Dermatology.

phase 2 Alpha-2 adrenergic agonist Alpha-2 adrenergic receptor Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Brimonidine Tartrate Gel (Brimonidine Tartrate Gel) — LEO Pharma. Brimonidine tartrate gel works by reducing the amount of norepinephrine in the body, which helps to decrease redness and swelling in the skin.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Brimonidine Tartrate Gel TARGET	Brimonidine Tartrate Gel	LEO Pharma	phase 2	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
Dexmetomidine intravenously	Dexmetomidine intravenously	KAT General Hospital	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Dexmedetomidine 0.5μg／kg	Dexmedetomidine 0.5μg／kg	Eye & ENT Hospital of Fudan University	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Brinzolamide/Brimonidine FC	Brinzolamide/Brimonidine FC	University Hospital of Patras	marketed	Carbonic anhydrase inhibitor / Alpha-2 adrenergic agonist combination	Carbonic anhydrase II; Alpha-2 adrenergic receptor
ropivacaine mixed with dexmedetomidine	ropivacaine mixed with dexmedetomidine	The First Hospital of Qinhuangdao	marketed	Local anesthetic combination with alpha-2 adrenergic agonist	Voltage-gated sodium channels (ropivacaine); alpha-2 adrenergic receptors (dexmedetomidine)
Low-dose Dexmedetomidine	Low-dose Dexmedetomidine	Tang-Du Hospital	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
Combigan Two Times Daily (BID)	Combigan Two Times Daily (BID)	Cornerstone Health Care, PA	marketed	Fixed-dose combination of alpha-2 adrenergic agonist and beta-blocker	Alpha-2 adrenergic receptor; beta-1 and beta-2 adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic agonist class)

USWM, LLC (dba US WorldMeds) · 2 drugs in this class
China International Neuroscience Institution · 1 drug in this class
Icahn School of Medicine at Mount Sinai · 1 drug in this class
Eye Therapies, LLC · 1 drug in this class
Galderma R&D · 1 drug in this class
Guangzhou Women and Children's Medical Center · 1 drug in this class
Derm Research, PLLC · 1 drug in this class
Irmandade da Santa Casa de Misericordia de Sao Paulo · 1 drug in this class
KK Women's and Children's Hospital · 1 drug in this class
American University of Beirut Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Brimonidine Tartrate Gel — Competitive Intelligence Brief. https://druglandscape.com/ci/brimonidine-tartrate-gel. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab